Dose modifications in adjuvant chemotherapy for solid organ malignancies: A systematic review of clinical trials

Asia-Pacific Journal of Clinical Oncology
Thiru PrasannaCatriona M McNeil

Abstract

Toxicities of systemic cancer therapies are often less frequently observed in clinical trials than in clinical practice, due to the careful selection of patients with fewer comorbidities. Although guidelines exist for the estimation of chemotherapy dose, clinical factors like age, comorbid illness and extremes of body habitus are not considered in the method of dose calculation, which can result in significant toxicity. We reviewed the referenced clinical trials from which the evidence-based curative-intent cancer treatment protocols were developed for EVIQ, which is an Australian government, online resource. This review shows that a significant proportion of patients in curative-intent clinical trials experience toxicities that result in dose modifications-dose reduction, dose delays or missed doses-despite strict selection criteria and intense monitoring. Thus, even in ideal, clinical-trial settings chemotherapy dose calculation remains imprecise and subject to adjustment as clinically appropriate. In real-world clinical practice, dose alterations or modifications in response to toxicities need to be thoroughly discussed and implemented with clear understanding of the patient with appropriate documentation. This review may be...Continue Reading

References

Nov 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G L RosnerR L Schilsky
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P KrischerS E Lipshultz
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Al-SarrafJ F Ensley
Feb 13, 2001·Critical Reviews in Oncology/hematology·A FléchonJ P Droz
Mar 17, 2001·JAMA : the Journal of the American Medical Association·R YancikJ W Yates
Aug 8, 2002·Journal of the National Cancer Institute·A David McCollumCharles S Fuchs
Feb 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J MillwardJ F Bishop
Aug 29, 2003·The New England Journal of Medicine·H Barton GrossmanE David Crawford
Jun 4, 2004·The New England Journal of Medicine·Thierry AndréUNKNOWN Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC)
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jacques BonneterreIsabelle Chapelle-Marcillac
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eleftherios P MamounasNorman Wolmark
Jun 3, 2005·The New England Journal of Medicine·Miguel MartinUNKNOWN Breast Cancer International Research Group 001 Investigators
Jun 24, 2005·The New England Journal of Medicine·Timothy WintonUNKNOWN National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators
Jul 1, 2005·The New England Journal of Medicine·Chris TwelvesWerner Scheithauer
Aug 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William P PetrosJeffrey R Marks
Feb 10, 2006·The New England Journal of Medicine·James A BonnerK Kian Ang
Jul 11, 2006·The New England Journal of Medicine·David Cunningham MAGIC Trial Participants
Nov 23, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henri RochéBernard Asselain
Dec 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen E JonesLina Asmar
May 1, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Imjai ChitapanaruxJudith Ford
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Debra A PattSharon H Giordano
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mary C PinderSharon H Giordano
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hyman B MussUNKNOWN Cancer and Leukemia Group B Experience
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joel TepperRobert Mayer
Apr 19, 2008·The New England Journal of Medicine·Joseph A SparanoNancy E Davidson
Apr 9, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carla M M PradoMichael B Sawyer
Jun 6, 2009·Japanese Journal of Clinical Oncology·Daisuke TakabatakeShigemitu Takashima
Jan 22, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S AntounM B Sawyer
Apr 30, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A SharmaS Bhasker
Sep 9, 2010·JAMA : the Journal of the American Medical Association·John P NeoptolemosUNKNOWN European Study Group for Pancreatic Cancer
May 1, 2008·Journal of Oncology Practice·Kathryn M FieldPeter Gibbs
Mar 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel G HallerHans-Joachim Schmoll
Oct 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alistair RingJack Cuzick
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Apr 5, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer J GriggsUNKNOWN American Society of Clinical Oncology

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved